Clinical Trial Update: Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

This update describes a Phase II salvage chemotherapy trial combining cisplatin and epirubicin for refractory germ cell tumors, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor

Drugs mentioned

• CISPLATIN (cisplatin)
• Epirubicin (epirubicin)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Germ Cell Tumor | Phase 2 | Status: TERMINATED